TD Cowen designated Kiniksa Pharmaceuticals as its top pharma pick with a $115 price objective, according to an analysis reported by mx.investing.com.
TD Cowen identified an opportunity in the pharmaceutical sector by designating Kiniksa Pharmaceuticals as its top pick, according to an analysis reported by mx.investing.com.
The firm’s analysis points to sustained commercial momentum for the company’s flagship product alongside potential value creation from its pipeline candidate.
The investment thesis centers on Kiniksa’s Arcalyst franchise for recurrent pericarditis. Analysts view this market as substantially subpenetrated despite five years of commercial history, leaving room for ongoing growth.
TD Cowen established a price objective of $115 for Kiniksa Pharmaceuticals based on a discounted cash flow analysis. Arcalyst has penetrated only 23% of the roughly 14,000 U.S. patients suffering from multiple recurrences of pericarditis. An additional 26,000 patients experiencing a first recurrence represent further market opportunity.
The company has reached only 18% of roughly 30,000 potential prescribers, indicating significant margin for expansion. Recent quarterly sales increases for the medication averaged about $25 million. TD Cowen’s 2027 revenue estimates assume a sequential quarterly growth of $12 million, sitting below the average seen across the previous six quarters.
A primary driver of future value is KPL-387, a proprietary IL-1 receptor antagonist. This candidate could offer subcutaneous quarterly dosing compared to the weekly administration required by Arcalyst.
This would reduce annual injections from 52 to 12. Phase III data are expected in the second half of 2027.
Given that KPL-387 is proprietary, unlike Arcalyst which incurs collaboration expenses representing approximately 35% of revenues, TD Cowen estimates the new drug could add approximately $6 to earnings per share based on Arcalyst 2027 revenue projections of approximately $1.3 billion, according to Investing. Additional potential could stem from another pipeline candidate named KPL-1161, indication expansion, and business development opportunities.
- Lifting Weights on a GLP-1 Is Critical – But Not Because It Saves Muscle
- Hanoi Obstetrics and Gynecology Hospital Applies Minimally Invasive Surfactant Therapy
- Apple announces App Store price changes in multiple countries, new California tax rules (newsylist.com)
- Dollar General's Four Test Buys: 30 Price Errors, 21 Against the Shopper (daybreakwire.com)